Scinai Immunotherapeutics
Filed with the SEC on · accession 0001213900-26-117154
SCNI filed a 6-K (foreign company report) with the SEC on Nov 9, 2026. Scinai Immunotherapeutics issued a press release reporting significant revenue growth in the first nine months of 2026 as its CDMO business expanded.
Scinai Immunotherapeutics issued a press release reporting significant revenue growth in the first nine months of 2026 as its CDMO business expanded. The Form 6-K furnishes the press release and incorporates it by reference into certain registration statements.
✦ Ask GOAX AI about this filing — what it means for SCNI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SCNI?
Click hereSCNI filed a 6-K (SEC filing). Scinai Immunotherapeutics issued a press release reporting significant revenue growth in the first nine months of 2026 as its CDMO business expanded. The Form 6-K furnishes the press release and incorporates it by reference into certain registration statements.
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Get alerts when SCNI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days